))
Winter 2025 Breast Cancer Research Round Up
Manage episode 477771970 series 3482052
Content provided by Breastcancer.org. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Breastcancer.org or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Can people diagnosed with metastatic hormone receptor-positive breast cancer avoid chemotherapy and take a CDK4/6 inhibitor instead? Do people diagnosed with DCIS need to have surgery? Will there soon be another oral selective estrogen degrader available?
Breastcancer.org medical advisor Dr. Kevin Fox explains the details of the studies and what they mean for you.
Listen to the episode to hear Dr. Fox discuss these studies:
- Young-PEARL: Ibrance plus Aromasin, along with ovarian suppression, offers better progression-free survival than Xeloda for pre-menopausal women with metastatic hormone receptor-positive, HER2-negative breast cancer who had previously received tamoxifen.
- PATINA: Adding Ibrance to standard-of-care first treatments for metastatic hormone receptor-positive, HER2-positive breast cancer increased progression-free survival by more than a year.
- EMBER-3:Imlunestrant led to longer progression-free survival than standard therapy if the cancer had an ESR1 mutation among people with estrogen receptor-positive, HER2-negative advanced-stage breast cancer. Adding Verzenio to imlunestrant improved progression-free survival compared to imlunestrant alone, whether the cancer had an ESR1-mutation or not.
- COMET: Can people with low-risk DCIS just be monitored instead of having surgery with or without radiation?
332 episodes
Share
